

Efficacy and safety of proton pump inhibitors and H2 receptor antagonists in the initial non-eradication treatment of duodenal ulcer: A network meta-analysis

XIANGBO MENG^{1*}, XIUYING ZHU^{1*}, BAIXUE LI^{1*}, JIBIN LIU¹, JIAWEI ZHAO²,
HUA WANG², QUANSHENG FENG¹ and YUE SU¹

¹School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610075;

²Acupuncture-Moxibustion and Orthopedic College, Hubei University of Chinese Medicine, Wuhan, Hubei 430061, P.R. China

Received December 17, 2022; Accepted February 16, 2023

DOI: 10.3892/etm.2023.11971

Abstract. The present network meta-analysis aimed to enhance the corresponding evidence with respect to the efficacy and safety of pharmaceuticals treatments. Frequentist network meta-analysis was used. Medical literature up to November 2022 was searched for randomized clinical trials assessing the efficacy and safety of these pharmaceuticals, either compared with each other or compared with placebo. With the exception of ranitidine (300 mg four times daily) and vonoprazan (20 mg once daily) having lower safety than placebo, the efficacy and safety of the remaining treatments were superior to placebo. Cimetidine (400 mg four times daily) and pantoprazole (40 mg once daily) were ranked first in terms of efficacy. The frequentist network meta-analysis shows that for cimetidine (except 400 mg once daily), famotidine, rabeprazole, ilaprazole, lansoprazole (except 7.5 mg once daily) and omeprazole (except 10 mg once daily or 30 mg once daily), the efficacy comparison between the different doses of each of the aforementioned pharmaceuticals did not indicate statistically significant differences. In conclusion, pantoprazole (40 mg

once daily) was the best choice for the initial non-eradication treatment of patients with duodenal ulcer, and cimetidine (400 mg twice daily), omeprazole (20 mg once daily), lansoprazole (15 mg once daily), ilaprazole (5 mg once daily) and rabeprazole (10 mg once daily) could be used as the first choice. If the aforementioned pharmaceuticals cannot be prescribed, famotidine (40 mg twice daily) is recommended.

Introduction

Duodenal ulcer (DU) is a common digestive system disease in the worldwide (1,2). Its complications, such as upper gastrointestinal bleeding or perforation, can cause death in patients with DU (3-5). In China, the duodenal ulcer is more common than gastric ulcer (44.69% vs. 37.42%). Approximately 61% of hospitalized patients with peptic ulcers have complications (46.45% of bleeding and 14.66% of perforation), and the average in-hospital mortality was 0.35% (6).

Although *Helicobacter pylori* eradication is beneficial to the healing of duodenal ulcer and reduce recurrence, non-eradication therapy is suitable for *Helicobacter pylori*-negative patients or without Hp examination (7,8). DU develops when the protective mechanisms of the gastrointestinal mucosa, such as mucus and bicarbonate secretion, are overwhelmed by the damaging effects of gastric acid and pepsin (9). Proton pump inhibitors (PPIs) and H2 receptor antagonists (H2RAs) are the leading pharmaceuticals for the initial non-eradication treatment of DU patients (10). The PPIs specifically inhibit the H⁺/K⁺-ATP enzymes of gastric parietal cells, resulting in the continuous and robust inhibition of gastric acid secretion and accelerated healing of ulcers (11). H2RAs mainly act on H2 receptors on gastric parietal cells, competitively inhibiting histamine and inhibiting basal gastric acid secretion (12).

Many systematic reviews and trials compared the effect of different H2RAs and PPIs, but there is no head-to-head comparison of different doses of these pharmaceuticals (13-19). The Japanese Society of Gastroenterology (JSGE) developed the evidence-based clinical practice guidelines for DU's initial non-eradication treatment, but there are no recommended doses of PPIs and H2RAs (10). A reappraisal of the available evidence to support clinical decision-making is timely.

Correspondence to: Professor Quansheng Feng or Dr Yue Su, School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, 1166 Liutai Avenue, Wenjiang, Chengdu, Sichuan 610075, P.R. China
E-mail: fengqs118@163.com
E-mail: suyue@cdutcm.edu.cn

*Contributed equally

Abbreviations: DU, duodenal ulcer; PPIs, proton pump inhibitors; H2RAs, H2 receptor antagonists; RCT, randomized controlled trial; RR, risk ratio; CI, confidence interval; SUCRA, surface under the cumulative ranking curve; CIM, cimetidine; FAM, famotidine; ILA, ilaprazole; LAN, lansoprazole; OME, omeprazole; PAN, pantoprazole; RAB, rabeprazole; RAN, ranitidine; VON, vonoprazan

Key words: DU, non-eradication therapy, PPIs, H2RAs, network meta-analysis

Therefore, we did a contemporaneous systematic review and network meta-analysis of RCTs of pharmaceuticals in non-eradication treatment DU.

Materials and methods

International certification registration. The study protocol is available on the International Prospective Register of Systematic Reviews with a registration number of CRD42020219564 and was prepared according to the guidelines of the Cochrane Multiple Interventions Methods Group (20).

Data sources and searches. We searched Cochrane Library, Embase, Medline, Web of Science, and Clinical Trials.gov databases from their inception until November 2022 for randomized clinical trials (RCTs) investigating different PPIs and H2RAs in initial non-eradication treatment of DU patients with no language restrictions. Additional studies were searched in the reference lists of all identified publications, including relevant meta-analyses. Regarding the search strategy, terms included the following items: ('Proton Pump Inhibitors' or 'PPI' or 'PPIs') and ('H2 Receptor Antagonists' or 'H2-receptor antagonists' or 'H2RAs') and ('Initial Non-eradication Treatment of DU patients' or 'Non-eradication of DU patients').

Study selection. All superiority, non-inferiority, phase II and III, single-blinded, and double-blinded trials were included. RCTs examining the effect of drugs (omeprazole, lansoprazole, rabeprazole, vonoprazan, pantoprazole, ilaprazole, ranitidine, cimetidine, famotidine) in adult patients (aged >18 years) with DU were eligible. The first period of randomized crossover trials was eligible for inclusion if they provided efficacy data before crossover. The definitions of DU considered within this network meta-analysis included endoscopically confirmed active DU. Trials that examined the efficacy of any dose of the drugs of interest and compared them with each other or placebo were considered eligible.

Two investigators (X. Zhu and X. Meng) did the literature search independently from one another. Two investigators (B. Li and Y. Su) evaluated all abstracts identified by searching for eligibility independently from one another. They obtained all potentially relevant papers and evaluated them in more detail, using pre-designed forms, to assess eligibility independently, according to the predefined criteria. We translated papers that were not in the English language. We resolved disagreements between investigators by discussion.

Data extraction and quality assessment. Two reviewers (J. Zhao and J. Liu) independently extracted data from original trial reports using a standardized form and then double-checked the extraction. We assessed the sources of bias using the Cochrane Collaboration's risk-of-bias tool addressing six domains (21). Two investigators (H. Wang and Q. Feng) independently completed the assessments, and discrepancies were discussed with a third party and resolved by consensus. Additionally, the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework were used to assess the quality of evidence contributing to each estimated network (22).

League table of all comparisons of efficacy and safety. Two independent reviewers (X. Meng and B. Li) assessed the risk of bias of these studies included in our analysis. Consistency between the two reviewers was reported. Any disagreement was solved by a third senior investigator (X. Zhu or J. Zhao). Studies were classified as having high risk of bias if one or more domains were rated as high risk of bias; low if five or more were rated as low risk of bias and none was rated as high risk of bias, and all other cases were assumed to regard as moderate risk.

Statistical analysis. We used frequentist network meta-analysis (23). The risk ratio (RR) and mean difference, with a 95% confidence interval (CI), for outcomes were summarized. The results were combined and analyzed, and the P-score of each treatment scheme was compared using the Haas ranking method (24). P-scores are based solely on point estimates and standard errors from the network estimates, and measure the mean extent of certainty that one intervention is better than another, averaged over all competing interventions (25). A design-by-treatment approach was used to verify the assumption of consistency in the analytical network (26).

Additionally, a funnel plot was drawn and a deviation test in combination with Egger test was conducted. A comparison-adjusted funnel plot was used to detect potential publication biases in the results between small and large studies. Global heterogeneity was assessed using the I^2 statistics, which incorporated the extent of heterogeneity and evaluated the extent of uncertainty in the estimated effect size locally. To assess whether the results were impacted by study characteristics (effect modifiers), the risk of bias (high, unclear, or low) was assessed. Additionally, to assess the robustness of the results, we used random effect models for sensitivity analysis. Comparison-adjusted funnel plots were obtained to investigate whether the integrated results were different between the imprecise and precise trials (27). All analyses were conducted using R 3.6.2 via the netmeta, version 1.1-0.

Results

Study characteristics. Sixty-five eligible studies, published between 1976 and 2022, corresponding to 15381 adults, were selected for pooled analyses (18,19,28-90). The literature search process is shown in Fig. 1. These trials evaluated 6 different PPIs (ilaprazole, omeprazole, lansoprazole, pantoprazole, rabeprazole, and vonoprazan) and 3 different H2RAs (cimetidine, ranitidine and famotidine). These studies have come from many countries (mainly China, Japan, United States, United Kingdom, Germany) and centers. Endoscopic examination was used to define the healing of duodenal ulcers after treatment. The patients' treatment courses were divided into three types: 46 studies were treated for four weeks, 14 studies were treated for six weeks, and five studies were treated for eight weeks. The baseline characteristics of the RCTs included are provided in Table SI (Supplementary File). We found a total of 89 studies about the application PPIs and H2RAs in initial non-eradication treatment of DU patients in the past five years. Most of them are non-RCT, data not extractable and no fixed dose of the drug used. Therefore, only one study was included in the criteria, and the others were not included in this study.




Figure 1. Study selection process. RCT, randomized controlled trial; TEAE, treatment-emergent adverse event.

Quality of the included studies. According to the Cochrane Collaboration's tool, all of the studies were judged to be at low or unclear risk of bias for six domains. Disagreements were resolved by discussion. The method used to generate the randomization schedule and conceal treatment allocation was recorded and whether blinding was implemented for participants, personnel, and outcomes assessment, whether there was evidence of incomplete outcomes data and whether there was evidence of selective reporting of outcomes.

Risk of bias table of included studies. Two independent reviewers (X. Meng and B. Li) assessed the risk of bias of these studies included in our analysis. Consistency between the two reviewers was reported. Any disagreement was solved by a third senior investigator (X. Zhu or H. Wang). Studies were classified as having high risk of bias if one or more domains were rated as high risk of bias; low if five or more were rated as low risk of bias and none was rated as high risk of bias, and all other cases were assumed to regard as moderate risk. The risk of bias assessment of the trials included in this study is presented in Table SII.

Network meta-analysis results. We assessed the efficacy and safety of 6 different PPIs (ilaprazole, omeprazole, lansoprazole, pantoprazole, rabeprazole, and vonoprazan) and 3 different H2RAs (cimetidine, ranitidine and famotidine) for initial non-eradication treatment of DU. There are different doses of the ilaprazole, omeprazole, lansoprazole, pantoprazole, rabeprazole, vonoprazan, cimetidine, ranitidine, and famotidine (3, 5, 4, 1, 2, 1, 6, 3, 4, respectively). Fig. 2 shows the network of eligible comparisons for ulcer healing rate.

Efficacy of the ulcer healing rate. Concerning an increase in the ulcer healing rate, our network meta-analysis included 65 RCTs involving the administration of 6 different PPIs and three different H2RAs patients. A placebo was used as a

reference. We found significant differences in efficacy between all the drugs and the placebo. Compared with the placebo, the included pharmaceuticals significantly increased the ulcer healing rate (Fig. 3). CIM 400 mg four times daily and PAN 40 mg once daily were ranked first (P -score=0.88) in 65 RCTs (RR 3.27, 95% CI 1.18-9.07; RR 1.95, 95% CI 1.72-2.22 respectively). Quantifying heterogeneity/inconsistency: $\tau^2=0.0006$; $\tau=0.0254$; $I^2=24.4\%$ [0.0%; 44.1%]. Results of the pairwise comparison are indicated by the RRs and 95% CIs in Table SIII. There were no significant statistical differences in different doses of the CIM (300 mg four times daily, 400 mg four times daily, 400 mg twice daily), FAM (20 mg twice daily, 40 mg once daily, 40 mg twice daily, 80 mg once daily), RAB (10 mg once daily, 20 mg once daily), ILA (5 mg once daily, 10 mg once daily, 20 mg once daily), LAN (15 mg once daily, 30 mg once daily, 60 mg once daily), OME (20 mg once daily, 40 mg once daily, 60 mg once daily).

Safety of TEAE (Treatment-emergent adverse event). Our network meta-analysis included 57 RCTs, reporting the administration of 6 different PPIs and three different H2RAs among 14788 DU patients. There was no statistically significant association between the nine drugs and the treatment-emergent adverse event compared with the placebo (Fig. 4). Results of the pairwise comparisons are indicated by the RRs and 95% CIs in Table SIII. FAM 20 mg twice daily was significantly less likely to lead to adverse events than RAN 300 mg four times daily, VON 20 mg once daily, and placebo. FAM 40 mg once daily was significantly less likely lead to adverse events than RAN 150 mg twice daily, RAN 300 mg four times daily, RAN 300 mg once daily, VON 20 mg once daily and placebo. FAM 40 mg twice daily was significantly less likely to lead to adverse events than VON 20 mg once daily. ILA 10 mg once daily was significantly less likely to lead to adverse events than RAN 300 mg four times daily, RAN 300 mg once daily, and VON 20 mg once daily.




Figure 2. Network meta-analysis of eligible comparisons for efficacy and safety. (A) Efficacy. (B) Safety. The width of the lines represents the number of studies and the size of the node represents the total sample size. CIM, cimetidine; FAM, famotidine; ILA, ilaprazole; LAN, lansoprazole; OME, omeprazole; PAN, pantoprazole; RAB, rabeprazole; RAN, ranitidine; VON, vonoprazan.




Figure 3. Result of network meta-analysis for efficacy. Contrast to placebo means that all patients taking active drugs were compared with those taking placebo. CIM, cimetidine; FAM, famotidine; ILA, ilaprazole; LAN, lansoprazole; OME, omeprazole; PAN, pantoprazole; RAB, rabeprazole; RAN, ranitidine; VON, vonoprazan; RR, risk ratio; CI, confidence interval.

Ranking of efficacy and safety of all included pharmaceuticals. We used the calculated p-scores to rank the efficacy and safety of the nine drugs included in our study (Table I; Fig. 5).

A higher p-score indicated higher efficacy or safety. Among all the drug pharmaceuticals, CIM 400 mg four times daily and PAN 40 mg once daily had the highest efficacy, with a p-score




Figure 4. Result of network meta-analysis for the safety of treatment-emergent adverse events. Contrast to Placebo meant that all patients taking active drugs were compared with those taking placebo. CIM, cimetidine; FAM, famotidine; ILA, ilaprazole; LAN, lansoprazole; OME, omeprazole; PAN, pantoprazole; RAB, rabeprazole; RAN, ranitidine; VON, vonoprazan; RR, risk ratio; CI, confidence interval.

of 0.88, while FAM 40 mg once daily and ILA 10 mg once daily were associated with the highest safety (p-score=0.64). RAN 300 mg four times daily (p-score=0.14) and VON 20 mg once daily (p-score=0.22) had lower safety than placebo (p-score=0.33).

Small-study effect analysis. The results of the comparison-adjusted funnel plots suggested that there may not be small-study effects for efficacy and safety (Egger test; $P>0.05$) (Fig. 6).

Discussion

This study is the first network meta-analysis to specifically evaluate the efficacy and safety of different doses of PPIs and H2RAs for the initial non-eradication treatment of duodenal ulcer (DU) patients. The direct and indirect comparison results showed some evidence from RCTs. Firstly, H2RAs and PPIs were found to perform significantly better than the placebo for increasing the ulcer healing rate. Concerning the TEAE rate, the pharmaceuticals included in this study were comparable to the placebo. Secondly, as refer to the ulcer healing rate, we did find there was no significant statistical differences in different doses of the CIM, FAM, RAB, ILA, LAN, OME. For these different pharmaceuticals, FAM 20 mg twice daily, RAB 10 mg once daily, ILA 5 mg once daily, LAN 15 mg once daily, and OME 20 mg once daily should be prescribed in the clinic considering the economy and convenience of taking medicine. Thirdly,

150 mg twice daily is the best choice for RAN, RAN 300 mg four times daily and VON 20 mg once daily needs more studies to confirm its safety. Lastly, CIM 400 mg four times daily and PAN 40 mg once daily had the highest P-scores of ulcer healing rate, but there is a significant heterogeneity of CIM 400 mg four times daily treatment. Moreover, PAN 40 mg once daily treatment was ranked twelfth for the TEAE rate.

PPI is not only the most recommended drug in the guide, but also the first drug in clinical practice. Although it is accompanied by long-term side effects, such as long-term administration of PPI will lead to gland atrophy, atrophic gastritis and gastric polyps. But its side effects are completely avoidable. In order to avoid such side effects or reduce the chance of occurrence, we can also take orally rebapide tablets, teprenone capsules and other drugs that promote the synthesis of endogenous prostaglandins, improve gastric circulation and protect gastric mucosa. If atrophic gastritis occurs, it can also be reversed or prevented from further development by drugs. Gastric polyps can be treated by endoscopic forceps, argon ion coagulation, ligation, submucosal dissection or resection (91). Therefore, the purpose of this study is to seek the appropriate dose and the best clinical dose to avoid the side effects of overuse and overuse. If PPIs cannot be prescribed, H2RAs are recommended (10). And Dr. Shi believes that with the progress of treatment, it is very necessary to adjust the drug dosage to obtain higher clinical efficacy (92). So this study focuses on the best dose of PPI for DU. But there are no recommended doses of PPIs and H2RAs. In our study, according to the P-scores of efficacy and safety,




Figure 5. P-score values of total efficacy and safety. CIM, cimetidine; FAM, famotidine; ILA, ilaprazole; LAN, lansoprazole; OME, omeprazole; PAN, pantoprazole; RAB, rabeprazole; RAN, ranitidine; VON, vonoprazan.




Figure 6. Comparison-adjusted funnel plots of total efficacy and safety. (A) Total efficacy. (B) Safety.

we recommend PAN 40 mg once daily (4 weeks) as the best choice treatment for DU patients. This is also confirmed by the research results of Dr. Huang and Dr. Li which suggested that

pantoprazole 40 mg once daily was the best choice for the treatment of DU patients (92,94). Similarly, a previous meta-analysis did find PAN (40 mg/day) seems to be the most cost-effective

Table I. P-score values of total efficacy and safety.

Treatments	P-scores of efficacy	P-scores of safety
CIM (300 mg four times daily)	0.3040679	0.4848278
CIM (400 mg four times daily)	0.8802221	0.4416666
CIM (400 mg once daily)	0.1501962	0.5319926
CIM (400 mg twice daily)	0.7292859	0.5109288
CIM (600 mg twice daily)	0.6841244	0.4053628
CIM (800 mg once daily)	0.1604934	0.5654400
FAM (20 mg twice daily)	0.4414836	0.7262596
FAM (40 mg once daily)	0.3268190	0.7723887
FAM (40 mg twice daily)	0.4674790	0.6834608
FAM (80 mg once daily)	0.2618819	0.6866390
ILA (10 mg once daily)	0.8006744	0.7749225
ILA (20 mg once daily)	0.5291277	0.5026243
ILA (5 mg once daily)	0.7145607	0.5314908
LAN (15 mg once daily)	0.6276334	0.5608376
LAN (30 mg once daily)	0.6235095	0.3432118
LAN (60 mg once daily)	0.7361912	0.3544614
LAN (7.5 mg once daily)	0.0897389	0.6112681
OME (10 mg once daily)	0.1256739	0.3609625
OME (20 mg once daily)	0.6589973	0.6184667
OME (30 mg once daily)	0.4380268	0.4796125
OME (40 mg once daily)	0.6097252	0.3449109
OME (60 mg once daily)	0.8340756	0.6738167
PAN (40 mg once daily)	0.8788211	0.5564456
Placebo	0.0010943	0.3321135
RAB (10 mg once daily)	0.6785481	0.4551692
RAB (20 mg once daily)	0.8067308	0.5436169
RAN (150 mg twice daily)	0.3199518	0.4475938
RAN (300 mg four times daily)	0.3816410	0.1400162
RAN (300 mg once daily)	0.2079667	0.3385505
VON (20 mg once daily)	0.5312583	0.2209416

CIM, cimetidine; FAM, famotidine; ILA, ilaprazole; LAN, lansoprazole; OME, omeprazole; PAN, pantoprazole; RAB, rabeprazole; RAN, ranitidine; VON, vonoprazan.

option in China (95). We also recommend CIM 400 mg twice daily (4 weeks), OME 20 mg once daily (4 weeks or 6 weeks), LAN 15 mg once daily (4 weeks), ILA 5 mg once daily (4 weeks), and RAB 10 mg once daily (4 weeks or 6 weeks) can be used as the first choice in the treatment of patients with duodenal ulcer. If the pharmaceuticals mentioned above cannot be prescribed, FAM 40 mg twice daily (8 weeks) is recommended. Our study provides a reasonable dosage and optimal choice for initial non-eradication treatment of duodenal ulcers.

This study is a network meta-analysis to explore the efficacy and safety of different doses of pharmaceuticals containing PPIs, H2RAs, and a placebo. Based on direct and indirect evidence, we provide a comprehensive preliminary ranking of these drugs regarding their effects on duodenal ulcer healing rate and TEAE rate, which could provide a basis for future clinical research. However, this study has some limitations, the allocation concealment are assessed unclear in most of the studies; the incomplete outcome data and selective reporting are

assessed unclear in some studies, there are two studies assessed as high risk. The quality of these studies potentially threatened the validity of our study. Notwithstanding these limitations, the findings from this network meta-analysis represent the most comprehensive currently available evidence base to guide the initial non-eradication treatment of DU in adults.

At present, some studies have shown that mucosal protection therapy combined with PPI has a good effect on DU, but in terms of single efficacy, PPI is better than mucosal protection therapy (96). According to 'Evidence-based Clinical Practice Guidelines for Peptic Ulcer Disease 2015', PPI is recommended for line drugs (97). If PPI cannot be prescribed, H2RA is recommended. So this study focuses on the best dose of PPI for DU. In conclusion, these PPIs and H2RAs are effective and safe for initial non-eradication treatment of DU. The results suggested that pantoprazole 40 mg once daily (4 weeks) was the best choice for the initial non-eradication treatment of DU patients, cimetidine 400 mg twice daily (4 weeks), omeprazole 20 mg once daily

(4 weeks or 6 weeks), lansoprazole 15 mg once daily (4 weeks), ilaprazole 5 mg once daily (4 weeks), and rabeprazole 10 mg once daily (4 weeks or 6 weeks) could be used as the first choice. If the pharmaceuticals mentioned above cannot be prescribed, famotidine 40 mg twice daily (8 weeks) is recommended.

Acknowledgements

Not applicable.

Funding

The present study was supported by the Science and Technology Project of Sichuan Province (grant nos. 2022YFS0409 and 2020YFS0301), The National Key Research and Development Program of China (grant no. 2018YFC1704104) and Chengdu University of Traditional Chinese Medicine Foundation (grant no. BSH2020014).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

XM and XZ confirm the authenticity of all the raw data. XM, XZ, QF and YS conceived and designed the current study, defined the content of the research, conducted literature search, performed statistical analysis, and prepared and edited the manuscript. BL and HW are the guarantors of study integrity, designed the current study, defined the content of the research and reviewed the manuscript. JL and JZ conducted the literature search, acquired data and performed statistical analysis. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

- Kavitt RT, Lipowska AM, Anyane-Yeboah A and Gralnek IM: Diagnosis and treatment of peptic ulcer disease. *Am J Med* 132: 447-456, 2019.
- Lau JY, Barkun A, Fan DM, Kuipers EJ, Yang YS and Chan FK: Challenges in the management of acute peptic ulcer bleeding. *Lancet* 381: 2033-2043, 2013.
- Dadfar A and Edna TH: Epidemiology of perforating peptic ulcer: A population-based retrospective study over 40 years. *World J Gastroenterol* 26: 5302-5313, 2020.
- Thorsen K, Søreide JA, Kvaløy JT, Glomsaker T and Søreide K: Epidemiology of perforated peptic ulcer: Age- and gender-adjusted analysis of incidence and mortality. *World J Gastroenterol* 19: 347-354, 2013.
- Malfertheiner P, Chan FK and McColl KE: Peptic ulcer disease. *Lancet* 374: 1449-1461, 2009.
- Zheng Y, Xue M, Cai Y, Liao S, Yang H, Wang Z, Wang X, Zhang X, Qian J and Wang L: Hospitalizations for peptic ulcer disease in China: Current features and outcomes. *J Gastroenterol Hepatol* 35: 2122-2130, 2020.
- Ford AC, Delaney BC, Forman D and Moayyedi P: Eradication therapy in *Helicobacter pylori* positive peptic ulcer disease: Systematic review and economic analysis. *Am J Gastroenterol* 99: 1833-1855, 2004.
- Treiber G and Lambert JR: The impact of *Helicobacter pylori* eradication on peptic ulcer healing. *Am J Gastroenterol* 93: 1080-1084, 1998.
- Sung JJ, Kuipers EJ and El-Serag HB: Systematic review: The global incidence and prevalence of peptic ulcer disease. *Aliment Pharmacol Ther* 29: 938-946, 2009.
- Kamada T, Satoh K, Itoh T, Ito M, Iwamoto J, Okimoto T, Kanno T, Sugimoto M, Chiba T, Nomura S, *et al*: Evidence-based clinical practice guidelines for peptic ulcer disease 2020. *J Gastroenterol* 56: 303-322, 2021.
- Savarino V, Mela GS, Zentilin P, Bisso G, Pivari M, Vigneri S, Termini R, Fiorucci S, Usai P, Malesci A and Celle G: Comparison of 24-h control of gastric acidity by three different dosages of pantoprazole in patients with duodenal ulcer. *Aliment Pharmacol Ther* 12: 1241-1247, 1998.
- Lamers CB: The changing role of H2-receptor antagonists in acid-related diseases. *Eur J Gastroenterol Hepatol* 8 (Suppl 1): S3-S7, 1996.
- Ji XQ, Du JF, Chen G, Chen G and Yu B: Efficacy of ilaprazole in the treatment of duodenal ulcers: A meta-analysis. *World J Gastroenterol* 20: 5119-5123, 2014.
- Poynard T, Lemaire M and Agostini H: Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. *Eur J Gastroenterol Hepatol* 7: 661-665, 1995.
- Eriksson S, Långström G, Rikner L, Carlsson R and Naesdal J: Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: A meta-analysis. *Eur J Gastroenterol Hepatol* 7: 467-475, 1995.
- Bamberg P, Caswell CM, Frame MH, Lam SK and Wong EC: A meta-analysis comparing the efficacy of omeprazole with H2-receptor antagonists for acute treatment of duodenal ulcer in Asian patients. *J Gastroenterol Hepatol* 7: 577-585, 1992.
- Hou XH, Meng F, Wang J, Sha W, Chiu CT, Chung WC, Gu L, Kudou K, Chong CF and Zhang S: 995 phase 3 Study evaluating the efficacy and safety of Vonoprazan 20 mg versus lansoprazole 30 mg in the treatment of endoscopically confirmed duodenal ulcers in Asian subjects with or without *Helicobacter pylori* infection. *Gastroenterology* 158: S197-S198, 2020.
- Hawkey CJ, Long RG, Bardhan KD, Wormsley KG, Cochran KM, Christian J and Moules IK: Improved symptom relief and duodenal ulcer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine. *Gut* 34: 1458-1462, 1993.
- McFarland RJ, Bateson MC, Green JR, O'Donoghue DP, Dronfield MW, Keeling PW, Burke GJ, Dickinson RJ, Shreeve DR, Peers EM, *et al*: Omeprazole provides quicker symptom relief and duodenal ulcer healing than ranitidine. *Gastroenterology* 98: 278-283, 1990.
- Chaimani A, Caldwell DM, Li T, Higgins JPT and Salanti G: Additional considerations are required when preparing a protocol for a systematic review with multiple interventions. *J Clin Epidemiol* 83: 65-74, 2017.
- Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP and Thomas J: Updated guidance for trusted systematic reviews: A new edition of the Cochrane Handbook for systematic reviews of interventions. *Cochrane Database Syst Rev* 10: ED000142, 2019.
- Salanti G, Del Giovane C, Chaimani A, Caldwell DM and Higgins JP: Evaluating the quality of evidence from a network meta-analysis. *PLoS One* 9: e99682, 2014.
- Greco T, Edefonti V, Biondi-Zoccai G, Decarli A, Gasparini M, Zangrillo A and Landoni G: A multilevel approach to network meta-analysis within a frequentist framework. *Contemp Clin Trials* 42: 51-59, 2015.
- Devall AJ, Papadopoulos A, Podsek M, Haas DM, Price MJ, Coomarasamy A and Gallos ID: Progestogens for preventing miscarriage: A network meta-analysis. *Cochrane Database Syst Rev* 4: CD013792, 2021.

25. Burr NE, Gracie DJ, Black CJ and Ford AC: Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: Systematic review and network meta-analysis. *Gut* 71: 1976-1987, 2021.
26. Higgins JP, Jackson D, Barrett JK, Lu G, Ades AE and White IR: Consistency and inconsistency in network meta-analysis: Concepts and models for multi-arm studies. *Res Synth Methods* 3: 98-110, 2012.
27. Chaimani A, Higgins JP, Mavridis D, Spyridonos P and Salanti G: Graphical tools for network meta-analysis in STATA. *PLoS One* 8: e76654, 2013.
28. Blackwood WS, Maudgal DP, Pickard RG, Lawrence D and Northfield TC: Cimetidine in duodenal ulcer: Controlled trial. *Lancet* 2: 174-176, 1976.
29. Gustavsson S, Adami HO, Lööf L, Nyberg A and Nyrén O: Rapid healing of duodenal ulcers with omeprazole: Double-blind dose-comparative trial. *Lancet* 2: 124-125, 1983.
30. Barbara L, Corinaldesi R, Bianchi Porro G, Lazzaroni M, Blasi A, Mangiameli A, Carratelli L, Wilkins A, Cheli R, Bovero E, *et al*: Famotidine in the management of duodenal ulcer: Experience in Italy. *Digestion* 32 (Suppl 1): S24-S31, 1985.
31. Prichard PJ, Rubinstein D, Jones DB, Dudley FJ, Smallwood RA, Louis WJ and Yeomans ND: Double blind comparative study of omeprazole 10 mg and 30 mg daily for healing duodenal ulcers. *Br Med J* 290: 601-603, 1985.
32. Simon B, Dammann HG, Jakob G, Miederer SE, Müller P, Ottenjann R, Paul F, Scholten T, Schütz E, Seifert E, *et al*: Famotidine versus ranitidine for the short-term treatment of duodenal ulcer. *Digestion* 32 (Suppl 1): S32-S37, 1985.
33. Arcidiacono R, Benvestito V, Bonomo GM, Bottari M, Buscarini L, Camarri E, Celle G, Coltorti M, Di Matteo S, Dobrilla G, *et al*: Comparison between ranitidine 150 mg b.d. and ranitidine 300 mg nocte in the treatment of duodenal ulcer. *Int J Clin Pharmacol Ther Toxicol* 24: 381-384, 1986.
34. Bardhan KD, Bianchi Porro G, Bose K, Daly M, Hinchliffe RF, Jonsson E, Lazzaroni M, Naesdal J, Rikner L and Walan A: A comparison of two different doses of omeprazole versus ranitidine in treatment of duodenal ulcers. *J Clin Gastroenterol* 8: 408-413, 1986.
35. Hirschowitz BI, Berenson MM, Berkowitz JM, Bright-Asare P, DeLuca VA Jr, Eshelman FN, Font RG, Griffin JW Jr, Kozarek RA, McCray RS, *et al*: A multicenter study of ranitidine treatment of duodenal ulcers in the United States. *J Clin Gastroenterol* 8: 359-366, 1986.
36. Lee FI, Reed PI, Crowe JP, McIsaac RL and Wood JR: Acute treatment of duodenal ulcer: A multicentre study to compare ranitidine 150 mg twice daily with ranitidine 300 mg once at night. *Gut* 27: 1091-1095, 1986.
37. McCullough AJ: A multicenter, randomized, double-blind study comparing famotidine with ranitidine in the treatment of active duodenal ulcer disease. *Am J Med* 81: 17-24, 1986.
38. Rohner HG and Gugler R: Treatment of active duodenal ulcers with famotidine. A double-blind comparison with ranitidine. *Am J Med* 81: 13-16, 1986.
39. Barbara L, Blasi A, Cheli R, Corinaldesi R, Dobrilla G, Francavilla A, Rinetti M, Vezzadini P, Abbiati R, Gradnik R, *et al*: Omeprazole vs. ranitidine in the short-term treatment of duodenal ulcer: An Italian multicenter study. *Hepatogastroenterology* 34: 229-232, 1987.
40. Dobrilla G, De Pretis G, Piazzi L, Boero A, Camarri E, Crespi M, Fontana G, Ideo G, Manenti F, Marengo G, *et al*: Comparison of once-daily bedtime administration of famotidine and ranitidine in the short-term treatment of duodenal ulcer. A multicenter, double-blind, controlled study. *Scand J Gastroenterol Suppl* 134: 21-28, 1987.
41. Gitlin N, McCullough AJ, Smith JL, Mantell G and Berman R: A multicenter, double-blind, randomized, placebo-controlled comparison of nocturnal and twice-a-day famotidine in the treatment of active duodenal ulcer disease. *Gastroenterology* 92: 48-53, 1987.
42. Kimmig JM: Acute therapy of duodenal ulcer. Comparison of famotidine with ranitidine in a single evening dosage. *Fortschritte der Medizin* 105: 72-76, 1987.
43. Archambault AP, Pare P, Bailey RJ, Navert H, Williams CN, Freeman HJ, Baker SJ, Marcon NE, Hunt RH, Sutherland L, *et al*: Omeprazole (20 mg daily) versus cimetidine (1200 mg daily) in duodenal ulcer healing and pain relief. *Gastroenterology* 94: 1130-1134, 1988.
44. Hartmann H and Fölsch UR: Famotidine versus cimetidine in the treatment of acute duodenal ulcer. Double-blind, randomized clinical trial comparing nocturnal administration of 40 mg famotidine to 800 mg cimetidine. *Digestion* 39: 156-161, 1988.
45. Young MD, Lottes SR and Webb LA: An evaluation of cimetidine and ranitidine in the pain relief and acute healing of duodenal ulcer disease. *Clin Ther* 10: 543-552, 1988.
46. Alcalá Santaella R, Guardia J, Pajares J, Piqué J, Pita L, Álvarez E, Castellanos P, Guarner L, Ortiz J, Pesquera R, *et al*: A multicentre, randomized, double-blind study comparing nocte famotidine or ranitidine for the treatment of active duodenal ulceration. *Aliment Pharmacol Ther* 3: 103-110, 1989.
47. Al-Mofleh I, Mayet I, Al-Rashed R, Al-Faleh F, Al-Aska AK and Laajam MA: Efficacy of single-daily doses of H₂-blockers in duodenal ulcer: Comparison of cimetidine and ranitidine in a double-blind controlled trial. *Curr Ther Res Clin Exp* 46: 399-403, 1989.
48. Chelvam P, Goh KL, Leong YP, Leela MP, Yin TP, Ahmad H, Jalleh R, Wong NW, Lee HB and Mahendran T: Omeprazole compared with ranitidine once daily in the treatment of duodenal ulcer. *J Gastroenterol Hepatol* 4 (Suppl 2): S53-S61, 1989.
49. Crowe JP, Wilkinson SP, Bates CM, Willoughby CP, Peers EM and Richardson PD: Symptom relief and duodenal ulcer healing with omeprazole or cimetidine. *Aliment Pharmacol Ther* 3: 83-91, 1989.
50. Delvaux M, Hagège CG and Ribet A: Comparative efficacy of famotidine and ranitidine in the treatment of acute-phase duodenal ulcer. A French comparative therapeutic trial. *Gastroenterol Clin Biol* 13: 1055-1059, 1989.
51. Lauritsen K, Andersen BN, Havelund T, Laursen LS, Hansen J, Eriksen J, Jørgensen T and Rask-Madsen J: Effect of 10 mg and 20 mg omeprazole daily on duodenal ulcer: Double-blind comparative trial. *Aliment Pharmacol Ther* 3: 59-67, 1989.
52. Lee FI, Booth SN, Cochran KM, Crowe J, Dickinson RJ, Kennedy NP, Cottrell J and Mann SG: Single night-time doses of 40 mg famotidine or 800 mg cimetidine in the treatment of duodenal ulcer. *Aliment Pharmacol Ther* 3: 505-512, 1989.
53. Mulder CJ, Tijtgaat GN, Cluysenaer OJ, Nicolai JJ, Meyer WW, Hazenberg BP, Vogten AJ, Gerrits C and Stuifbergen WH: Omeprazole (20 mg o.m.) versus ranitidine (150 mg b.d.) in duodenal ulcer healing and pain relief. *Aliment Pharmacol Ther* 3: 445-451, 1989.
54. Page MC, Lacey LA, Mills JG and Wood JR: Can higher doses of an H₂-receptor antagonist accelerate duodenal ulcer healing? *Aliment Pharmacol Ther* 3: 425-433, 1989.
55. Rodrigo L, Viver J, Conchillo F, Barrio E, Forné M, Zozaya JM, Alvarez A, Dieguez P, Muñoz M, Panés J, *et al*: A multicenter, randomized, double-blind study comparing famotidine with cimetidine in the treatment of active duodenal ulcer disease. *Digestion* 42: 86-92, 1989.
56. Kang JY, Guan R, Tay HH, Yap I, Wee A, Math MV and Labrooy SJ: Low-dose cimetidine in the acute treatment of duodenal ulcer. Comparison of a single nocturnal dose regimen with a twice daily regimen. *J Gastroenterol Hepatol* 5: 669-674, 1990.
57. Double blind comparative study of omeprazole and ranitidine in patients with duodenal or gastric ulcer: A multicentre trial. *Gut* 31: 653-656, 1990.
58. Popovic O, Dzambas D, Tasic T, Bidikov V, Jesenski T and Janosevic S: Omeprazole 20 mg o.m. vs. famotidine 40 mg h.s. in the treatment of duodenal ulcer. Multicenter double-blind randomized trial. *Gastroenterohepatoloski Arhiv* 9: 26-34, 1990.
59. Cochran KM: Famotidine, ranitidine and cimetidine in the treatment of duodenal ulcer: Two large international studies. *Eur J Gastroenterol Hepatol* 3: 527-531, 1991.
60. Londong W, Barth H, Dammann HG, Hengels KJ, Kleinert R, Müller P, Rohde H and Simon B: Dose-related healing of duodenal ulcer with the proton pump inhibitor lansoprazole. *Aliment Pharmacol Ther* 5: 245-254, 1991.
61. Delle Fave G, Annibale B, Franceschi M, Quatrini M, Cassetta MR and Torsoli A: Omeprazole versus famotidine in the short-term treatment of duodenal ulcer disease. *Aliment Pharmacol Ther* 6: 469-478, 1992.
62. Hotz J, Kleinert R, Grymbowski T, Hennig U and Schwarz JA: Lansoprazole versus famotidine: Efficacy and tolerance in the acute management of duodenal ulceration. *Aliment Pharmacol Ther* 6: 87-95, 1992.
63. Kumar TR, Naidu MU, Shobha JC, Reddy DN, Subhash S, Chaulal C, Prasad R and Babu S: Comparative study of omeprazole and famotidine in the treatment of duodenal ulcer. *Indian J Gastroenterol* 11: 73-75, 1992.

64. Lysy J, Karmeli F, Wengrower D and Rachmilewitz D: Effect of duodenal ulcer healing induced by omeprazole and ranitidine on the generation of gastroduodenal eicosanoids, platelet-activating factor, pepsinogen A, and gastrin in duodenal ulcer patients. *Scand J Gastroenterol* 27: 13-19, 1992.
65. Wang CY, Wang TH, Lai KH, Siauw CP, Chen PC, Yang KC, Tsai YT and Sung JL: Double-blind comparison of omeprazole 20 mg OM and ranitidine 300 mg NOCTE in duodenal ulcer: A Taiwan multi-centre study. *J Gastroenterol Hepatol* 7: 572-576, 1992.
66. Ahmed W, Qureshi H, Zuberi SJ and Alam SE: Omeprazole vs ranitidine in the healing of duodenal ulcer. *J Pak Med Assoc* 43: 111-112, 1993.
67. Misra SC, Dasarathy S and Sharma MP: Omeprazole versus famotidine in the healing and relapse of duodenal ulcer. *Aliment Pharmacol Ther* 7: 443-449, 1993.
68. Judmaier G and Koelz HR: Comparison of pantoprazole and ranitidine in the treatment of acute duodenal ulcer. *Pantoprazole-Duodenal Ulcer-Study Group. Aliment Pharmacol Ther* 8: 81-86, 1994.
69. Lanza F, Goff J, Scowcroft C, Jennings D and Greski-Rose P: Double-blind comparison of lansoprazole, ranitidine, and placebo in the treatment of acute duodenal ulcer. *Lansoprazole Study Group. Am J Gastroenterol* 89: 1191-1200, 1994.
70. Porro GB, Lazzaroni M, Cardelli A, Gasperoni S, De Berardinis F, Delle Fave G, Annibale B, Galeazzi R, Novelli G, Mazzeo F, *et al*: Pantoprazole vs omeprazole in the treatment of duodenal ulcer. *Argomenti di Gastroenterologia Clin* 7: 271-275, 1994.
71. Avner DL, Dorsch ER, Jennings DE and Greski-Rose PA: A comparison of three doses of lansoprazole (15, 30 and 60 mg) and placebo in the treatment of duodenal ulcer. *The Lansoprazole Study Group. Aliment Pharmacol Ther* 9: 521-528, 1995.
72. Beker JA, Bianchi Porro G, Bigard MA, Delle Fave G, Devis G, Gouerou H and Maier C: Double-blind comparison of pantoprazole and omeprazole for the treatment of acute duodenal ulcer. *Eur J Gastroenterol Hepatol* 7: 407-410, 1995.
73. Chang FY, Chiang CY, Tam TN, Ng WW and Lee SD: Comparison of lansoprazole and omeprazole in the short-term management of duodenal ulcers in Taiwan. *J Gastroenterol Hepatol* 10: 595-601, 1995.
74. Ekström P, Carling L, Unge P, Anker-Hansen O, Sjöstedt S and Sellström H: Lansoprazole versus omeprazole in active duodenal ulcer. A double-blind, randomized, comparative study. *Scand J Gastroenterol* 30: 210-215, 1995.
75. Rehner M, Rohner HG and Schepp W: Comparison of pantoprazole versus omeprazole in the treatment of acute duodenal ulceration-a multicentre study. *Aliment Pharmacol Ther* 9: 411-416, 1995.
76. Schepp W and Classen M: Pantoprazole and ranitidine in the treatment of acute duodenal ulcer. A multicentre study. *Scand J Gastroenterol* 30: 511-514, 1995.
77. Miszputen SJ, De PVM, Kondo M, Ferrari A, Zaterka S, Eisig JN, Chinzon D, De M, Maguilnik I, Vieira FEF, *et al*: Comparative multicentric study between omeprazole and ranitidine in duodenal ulcer. *GED* 16: 127-134, 1997.
78. Papp J, Döbrönte Z, Juhász L and Lonovics J: Evaluation of the effectiveness of pantoprazole and ranitidine in the treatment of duodenal ulcer. Result of an international multicenter study. *Orv Hetil* 138: 2863-2866, 1997 (In Hungarian).
79. Bardhan KD, Crowe J, Thompson RP, Trewby PN, Keeling PN, Weir D and Crouch SL: Lansoprazole is superior to ranitidine as maintenance treatment for the prevention of duodenal ulcer relapse. *Aliment Pharmacol Ther* 13: 827-832, 1999.
80. Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE and Humphries TJ: Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: A European multicentre study. *Aliment Pharmacol Ther* 13: 179-186, 1999.
81. Dobrilla G, Piazzi L and Fiocca R: Lansoprazole versus omeprazole for duodenal ulcer healing and prevention of relapse: A randomized, multicenter, double-masked trial. *Clin Ther* 21: 1321-1332, 1999.
82. Breiter JR, Riff D and Humphries TJ: Rabeprazole is superior to ranitidine in the management of active duodenal ulcer disease: Results of a Double-Blind, randomized North American study. *Am J Gastroenterol* 95: 936-942, 2000.
83. Meneghelli UG, Zaterka S, de Paula Castro L, Malafaia O and Lyra LG: Pantoprazole versus ranitidine in the treatment of duodenal ulcer: A multicenter study in Brazil. *Am J Gastroenterol* 95: 62-66, 2000.
84. Shim CS, Cho JY, Chung IS, Yang YS, Kim SW and Choi MG: Rabeprazole 10 mg versus omeprazole 20 mg in the treatment of duodenal ulcer: The Korean multicenter, comparative trial. *Korean J Gastrointestinal Endoscopy* 24: 76-83, 2002.
85. Ji S, Kim HS, Kim JW, Jee MK, Park KW, Uh Y, Lee DK, Song JS, Baik SK and Kwon SO: Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases. *J Gastroenterol Hepatol* 21: 1381-1387, 2006.
86. Ho KY, Kuan A, Zaño F, Goh KL, Mahachai V, Kim DY and Yoon HM: Randomized, parallel, double-blind comparison of the ulcer-healing effects of ilaprazole and omeprazole in the treatment of gastric and duodenal ulcers. *J Gastroenterol* 44: 697-707, 2009.
87. Wang L, Zhou L, Lin S, Hu H and Xia J: A New PPI, Ilaprazole compared with omeprazole in the treatment of duodenal ulcer a randomized double-blind multicenter trial. *J Clin Gastroenterol* 45: 322-329, 2011.
88. Wang L, Zhou L, Hu H, Lin S and Xia J: Ilaprazole for the treatment of duodenal ulcer: A randomized, double-blind and controlled phase III trial. *Curr Med Res Opin* 28: 101-109, 2012.
89. Miwa H, Uedo N, Watari J, Mori Y, Sakurai Y, Takanami Y, Nishimura A, Tatsumi T and Sakaki N: Randomised clinical trial: Efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers-results from two phase 3, non-inferiority randomised controlled trials. *Aliment Pharmacol Ther* 45: 240-252, 2017.
90. Fan L, Xianghong Q, Ling W, Ying H, Jielai X and Haitang H: Ilaprazole compared with rabeprazole in the treatment of duodenal ulcer: A randomized, double-blind, active-controlled, multicenter study. *J Clin Gastroenterol* 53: 641-647, 2019.
91. Wu HN: Comparison of different combinations of triple therapy in the treatment of *Helicobacter pylori* positive duodenal ulcer. *Yunnan Med* 38: 242-244, 2017.
92. Huang HY, Liu GF, Qi CX, Zhao YH and Wu J: Comparison of the efficacy of proton pump inhibitor high-dose combination and bismuth combination in the eradication of *Helicobacter pylori*. *Clin Focus* 37: 230-233, 2022.
93. Shi RL: Evaluation of rational use of proton pump inhibitors in 300 inpatients. *Chin Modern Doctor* 60: 92-95, 2022.
94. Li CY, Zhang J, Wang XH and Wang YN: Investigation and analysis of proton pump inhibitors in 3005 hospitalized patients. *Evaluation and Analysis of Drug Use in Chinese Hospitals* 17: 406-409, 2017.
95. Zhang J, Ge L, Hill M, Liang Y, Xie J, Cui D, Li X, Zheng W and He R: Standard-dose proton pump inhibitors in the initial Non-eradication treatment of duodenal ulcer: Systematic review, network Meta-analysis, and Cost-effectiveness analysis. *Front Pharmacol* 9: 1512, 2018.
96. Huang YZ: Clinical effect of gastric mucosal protector combined with proton pump inhibitor in the treatment of peptic ulcer with hemorrhage. *Chin Med Guide* 20: 29-32, 2022.
97. Satoh K, Yoshino J, Akamatsu T, Itoh T, Kato M, Kamada T, Takagi A, Chiba T, Nomura S, Mizokami Y, *et al*: Evidence-based clinical practice guidelines for peptic ulcer disease. *J Gastroenterol* 51: 177-94, 2016.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.